Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

67th Annual Scientific Sessions of the American College of Cardiology

10-12 March 2018, Orlando, Florida, USA

PlayHighlights from ACC.2018: Poster presentations

Highlights from ACC.2018: Poster presentations

Real-life experience with PCSK9 inhibition in familial hypercholesterolaemia Familial hypercholesteraemia (FH, inherited high cholesterol) is one of the key groups for whom PCSK9 inhibition is indicated. This prospective registry provided data on 44 patients with genetically verified FH attending a specialist lipid clinic in Norway….

read more »
Will the PCSK9 inhibitor trials change guidelines and practice?

Will the PCSK9 inhibitor trials change guidelines and practice?

Statins are the indisputable backbone of lipid-lowering therapy for prevention of atherosclerotic cardiovascular disease (ASCVD), with add-on ezetimibe proven to provide further benefit in high-risk patients.1 Yet it is clear that even with optimally tolerated statin therapy, a high residual cardiovascular risk persists. In ODYSSEY…

read more »
PlayODYSSEY Outcomes and FOURIER in context

ODYSSEY Outcomes and FOURIER in context

Highlights from ACC.2018 In the swirling milieu after presentation of the top-line data from ODYSSEY Outcomes, it is important to put the two cardiovascular outcomes studies in context, especially given the all-cause mortality benefit observed in ODYSSEY Outcomes but not in FOURIER.1,2  It is also…

read more »
PlayInclisiran marches on: ORION-4 cardiovascular outcomes study launches

Inclisiran marches on: ORION-4 cardiovascular outcomes study launches

Highlights from ACC.2018 The pace of development of inclisiran, an investigational GalNAc-conjugated RNA interference therapeutic, which reduces synthesis of PCSK9 protein in liver cells, thereby reducing liver cell LDL-receptor turnover, and lowering plasma LDL cholesterol levels is accelerating. Prior to ACC.2018, it was announced that…

read more »